Advertisement

Der Chirurg

, Volume 89, Issue 7, pp 505–509 | Cite as

Oligometastasierung beim Magen- und Ösophaguskarzinom

Aktuelle Studienlage und chirurgische Konzepte
Leitthema
  • 159 Downloads

Zusammenfassung

Die Rolle der Chirurgie gewinnt auch in metastasierten Tumorstadien zunehmend an Bedeutung. Bei kolorektalen Karzinomen mit einer limitierten Metastasierung kann sowohl in der synchronen als auch metachronen Situation durch eine komplette Tumorresektion ein onkologischer Benefit erzielt werden. Bei den Tumoren des oberen Gastrointestinaltraktes (OGI) ist der Stellenwert der Metastasenchirurgie bisher nicht abschließend geklärt, auch wenn retrospektive Analysen im Kontext einer multimodalen Therapie einen Überlebensvorteil suggerieren. Die aktuelle S3-Leitlinie spricht jedoch auf Basis der bisherigen Datenlage keine Empfehlung für eine chirurgische Therapie aus. Ziel der präoperativen Selektion muss es daher sein, Patienten mit einer vergleichsweise wenig aggressiven Tumorbiologie zu identifizieren. Die Ergebnisse der prospektiv-randomisierten RENAISSANCE/FLOT-5- und GASTRIPEC-Studien werden mit Spannung erwartet, um die Wertigkeit einer Metastasenchirurgie insbesondere auf das Überleben zu definieren.

Schlüsselwörter

Zytoreduktive Chirurgie Limitierte Metastasierung Karzinome des oberen Gastrointestinaltraktes Präoperatives Management Metastasenchirurgie 

Oligometastases in gastric and esophageal cancer

Current clinical trials and surgical concepts

Abstract

There is an increasing role of surgery even in metastatic tumor stages. In colorectal cancer patients with limited metastases, complete cytoreduction is able to offer long-term survival in synchronic as well as metachronic situations. In tumors of the upper gastrointestinal tract (UGIT), however, the impact of surgery in metastatic disease remains to be clarified. Even though several retrospective studies suggest prolonged survival, surgery is not recommended by the current German S3 guidelines for tumors of the UGIT. Appropriate selection of these particular patients that show less aggressive tumor biology will be the primary goal of preoperative evaluation. The results of the prospective randomized RENAISSANCE/FLOT-5 and GASTRIPEC studies are urgently awaited in order to gain more evidence on the impact of surgery in the management of oligometastases of the UGIT and especially on survival.

Keywords

Cytoreductive surgery Limited metastases Upper gastrointestinal cancer Preoperative management Surgery for metastatic disease 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

S. Beckert und A. Königsrainer geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Al-Batran SE, Goetze TO, Mueller DW et al (2017) The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI. BMC Cancer 17:893CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Al-Batran SE, Homann N, Pauligk C et al (2017) Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol 3:1237–1244CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Badgwell B, Roy-Chowdhuri S, Chiang YJ et al (2015) Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery. J Surg Oncol 111:875–881CrossRefPubMedGoogle Scholar
  4. 4.
    Boerner T, Graichen A, Jeiter T et al (2016) CRS-HIPEC prolongs survival but is not curative for patients with peritoneal carcinomatosis of gastric cancer. Ann Surg Oncol 23:3972–3977CrossRefPubMedGoogle Scholar
  5. 5.
    Chia CS, You B, Decullier E et al (2016) Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Is cure a possibility? Ann Surg Oncol 23:1971–1979CrossRefPubMedGoogle Scholar
  6. 6.
    Chiapponi C, Berlth F, Plum PS et al (2017) Oligometastatic disease in upper gastrointestinal cancer – How to proceed? Visc Med 33:31–34CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Choi SH, Kim SY, Park SH et al (2017) Diagnostic performance of CT, gadoxetate disodium-enhanced MRI, and PET/CT for the diagnosis of colorectal liver metastasis: systematic review and meta-analysis. J Magn Reson Imaging.  https://doi.org/10.1002/jmri.25852 Google Scholar
  8. 8.
    Desouza NM, Liu Y, Chiti A et al (2018) Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group. Eur J Cancer.  https://doi.org/10.1016/j.ejca.2017.12.012 PubMedGoogle Scholar
  9. 9.
    Fitzgerald TL, Brinkley J, Banks S et al (2014) The benefits of liver resection for non-colorectal, non-neuroendocrine liver metastases: a systematic review. Langenbecks Arch Surg 399:989–1000CrossRefPubMedGoogle Scholar
  10. 10.
    Glehen O, Gilly FN, Arvieux C et al (2010) Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 17:2370–2377CrossRefPubMedGoogle Scholar
  11. 11.
    Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10CrossRefPubMedGoogle Scholar
  12. 12.
    Holscher AH, Stahl M, Messmann H et al (2016) New S3 guideline for esophageal cancer: important surgical aspects. Chirurg 87:865–872CrossRefPubMedGoogle Scholar
  13. 13.
    Holzel D, Eckel R, Emeny RT et al (2010) Distant metastases do not metastasize. Cancer Metastasis Rev 29:737–750CrossRefPubMedGoogle Scholar
  14. 14.
    Huddy JR, Thomas RL, Worthington TR et al (2015) Liver metastases from esophageal carcinoma: is there a role for surgical resection? Dis Esophagus 28:483–487CrossRefPubMedGoogle Scholar
  15. 15.
    Ichida H, Imamura H, Yoshimoto J et al (2013) Pattern of postoperative recurrence and hepatic and/or pulmonary resection for liver and/or lung metastases from esophageal carcinoma. World J Surg 37:398–407CrossRefPubMedGoogle Scholar
  16. 16.
    Ichikawa H, Kosugi S, Nakagawa S et al (2011) Operative treatment for metachronous pulmonary metastasis from esophageal carcinoma. Surgery 149:164–170CrossRefPubMedGoogle Scholar
  17. 17.
    Iijima Y, Akiyama H, Atari M et al (2016) Pulmonary resection for metastatic gastric cancer. Ann Thorac Cardiovasc Surg 22:230–236CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Khomiakov V, Ryabov A, Bolotina LV et al (2017) Bidirectinal chemotherapy in gastric cncer (GC) with peritoneal carcinomatosis (PC) combining intravenous chemotherapy with intraperitoneal chemotherapy with low-dose cisplatin and doxorubicin administered as a pressurized aerosol: an open-label, phase-II study. J Clin Oncol.  https://doi.org/10.1200/JCO.2017.35.15_suppl.e15532 Google Scholar
  19. 19.
    Klumpp BD, Schwenzer N, Aschoff P et al (2013) Preoperative assessment of peritoneal carcinomatosis: intraindividual comparison of 18 F-FDG PET/CT and MRI. Abdom Imaging 38:64–71CrossRefPubMedGoogle Scholar
  20. 20.
    Ko Y, Kim J, Park JK et al (2017) Limited detection of small (≤ 10 mm) colorectal liver metastasis at preoperative CT in patients undergoing liver resection. PLoS ONE 12:e189797CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Kobayashi N, Kohno T, Haruta S et al (2014) Pulmonary metastasectomy secondary to esophageal carcinoma: long-term survival and prognostic factors. Ann Surg Oncol 21(Suppl 3):365–369CrossRefGoogle Scholar
  22. 22.
    Kong JH, Lee J, Yi CA et al (2012) Lung metastases in metastatic gastric cancer: pattern of lung metastases and clinical outcome. Gastric Cancer 15:292–298CrossRefPubMedGoogle Scholar
  23. 23.
    Konigsrainer I, Horvath P, Struller F et al (2014) Initial clinical experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in signet-ring cell gastric cancer with peritoneal metastases. J Gastric Cancer 14:117–122CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Liao YY, Peng NF, Long D et al (2017) Hepatectomy for liver metastases from gastric cancer: a systematic review. BMC Surg 17:14CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Markar SR, Mackenzie H, Mikhail S et al (2017) Surgical resection of hepatic metastases from gastric cancer: outcomes from national series in England. Gastric Cancer 20:379–386CrossRefPubMedGoogle Scholar
  26. 26.
    Markar SR, Mikhail S, Malietzis G et al (2016) Influence of surgical resection of hepatic metastases from gastric adenocarcinoma on long-term survival: systematic review and pooled analysis. Ann Surg 263:1092–1101CrossRefPubMedGoogle Scholar
  27. 27.
    Moehler M, Al-Batran SE, Andus T et al (2011) German S3-guideline “Diagnosis and treatment of esophagogastric cancer”. Z Gastroenterol 49:461–531CrossRefPubMedGoogle Scholar
  28. 28.
    Monig SP, Schiffmann LM (2016) Resection of advanced esophagogastric adenocarcinoma : extended indications. Chirurg 87:398–405CrossRefPubMedGoogle Scholar
  29. 29.
    Oki E, Tokunaga S, Emi Y et al (2016) Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302). Gastric Cancer 19:968–976CrossRefPubMedGoogle Scholar
  30. 30.
    Porschen R, Buck A, Fischbach W et al (2015) S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus (Langversion 1.0 – September 2015, AWMF-Registernummer: 021/023OL). Z Gastroenterol 53:1288–1347CrossRefPubMedGoogle Scholar
  31. 31.
    Rau B (2014) Prospective multicentric phase III study. Z Gastroenterol 52:262CrossRefPubMedGoogle Scholar
  32. 32.
    Schmidt T, Alldinger I, Blank S et al (2015) Surgery in oesophago-gastric cancer with metastatic disease: treatment, prognosis and preoperative patient selection. Eur J Surg Oncol 41:1340–1347CrossRefPubMedGoogle Scholar
  33. 33.
    Schmidt T, Monig SP (2017) Therapeutic approach in oligometastatic gastric and esophageal cancer. Chirurg 88:1024–1032CrossRefPubMedGoogle Scholar
  34. 34.
    Schmiegel W, Buchberger B, Follmann M et al (2017) S3-Leitlinie – Kolorektales Karzinom. Z Gastroenterol 55:1344–1498CrossRefPubMedGoogle Scholar
  35. 35.
    Shiono S, Kawamura M, Sato T et al (2008) Disease-free interval length correlates to prognosis of patients who underwent metastasectomy for esophageal lung metastases. J Thorac Oncol 3:1046–1049CrossRefPubMedGoogle Scholar
  36. 36.
    Spratt JS, Adcock RA, Muskovin M et al (1980) Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 40:256–260PubMedGoogle Scholar
  37. 37.
    Sugarbaker TA, Chang D, Koslowe P et al (1996) Patterns of spread of recurrent intraabdominal sarcoma. Cancer Treat Res 82:65–77CrossRefPubMedGoogle Scholar
  38. 38.
    Von Breitenbuch P, Boerner T, Jeiter T et al (2017) Laparoscopy as a useful selection tool for patients with prior surgery and peritoneal metastases suitable for multimodality treatment strategies. Surg Endosc.  https://doi.org/10.1007/s00464-017-5923-0 Google Scholar
  39. 39.
    Weichselbaum RR, Hellman S (2011) Oligometastases revisited. Nat Rev Clin Oncol 8:378–382CrossRefPubMedGoogle Scholar
  40. 40.
    Yamashita H, Niibe Y, Yamamoto T et al (2016) Lung stereotactic radiotherapy for oligometastases: comparison of oligo-recurrence and sync-oligometastases. Jpn J Clin Oncol 46:687–691CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Yang XJ, Huang CQ, Suo T et al (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 18:1575–1581CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Yonemura Y, Canbay E, Li Y et al (2016) A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol 42:1123–1131CrossRefPubMedGoogle Scholar
  43. 43.
    Yonemura Y, Elnemr A, Endou Y et al (2012) Effects of neoadjuvant intraperitoneal/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer. Int J Surg Oncol 2012:148420PubMedPubMedCentralGoogle Scholar
  44. 44.
    Yoshida Y, Imakiire T, Yoneda S et al (2014) Ten cases of resected solitary pulmonary metastases arising from gastric cancer. Asian Cardiovasc Thorac Ann 22:578–582CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Klinik für Allgemeine, Viszeral- und TransplantationschirurgieTübingenDeutschland

Personalised recommendations